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Acid retention during kidney failure induces
endothelin and aldosterone production which
lead to progressive GFR decline, a situation
ameliorated by alkali diet
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Rats with 5/6 nephrectomy have metabolic acidosis with a
progressive decline in the glomerular filtration rate (GFR)
ameliorated by endothelin and aldosterone antagonists and
by dietary alkali. Interestingly, rats with 2/3 nephrectomy
have no metabolic acidosis yet have a progressive GFR
decline induced by acid retention and ameliorated by dietary
alkali. Because patients without metabolic acidosis but with a
moderately reduced GFR have a progressive GFR decline,
ameliorated by oral sodium bicarbonate, we used rats with
2/3 nephrectomy to model these patients. Kidney acid
content, endothelin-1, and aldosterone (measured by
microdialysis) were higher in the rats with 2/3 nephrectomy
than those with a sham operation despite no differences in
plasma acid-base parameters. The GFR of the former but not
the latter was lower at 25 than at 1 week after nephrectomy.
Endothelin and aldosterone antagonism improved the
preservation of GFR; however, this remained lower at week
24 than at week 1. By contrast, the GFR at weeks 24 and
1 was not different if the rats were given dietary alkali to
normalize the kidney acid content. Antagonist of endothelin
and aldosterone yielded no added GFR benefit. Thus, our
study shows that (1) the decline in GFR in 2/3 nephrectomy is
mediated by acid retention-induced kidney endothelin and
aldosterone production; (2) receptor antagonism and dietary
alkali are not additive; and (3) dietary alkali better preserves
GFR than both endothelin and aldosterone receptor
antagonism.
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Prevention of complete kidney failure with its untoward
effects on length and quality of life includes addressing the
growing number of subjects with chronic kidney disease
(CKD).1 Although health-care providers appropriately focus
kidney-protective measures on subjects with advanced CKD
because of their more imminent threat of complete kidney
failure,2 the largest cadre of CKD subjects consists of those
with moderately reduced glomerular filtration rate (GFR)1 in
whom kidney-protective interventions are likely to have the
greatest benefit. Subjects with moderately reduced GFR can
have progressive GFR decline despite what is currently
considered to be optimal kidney-protective interventions
including blood pressure reduction with regimens that
include angiotensin-converting enzyme (ACE) inhibitors.3,4
Daily oral NaHCO3 ameliorated progressive GFR decline in
subjects with moderately reduced GFR,4 suggesting a novel
kidney protection strategy for such subjects. Determining
mechanisms by which dietary NaHCO3 helps preserve GFR
will enhance understanding of factors that mediate nephrop-
athy progression and possibly lead to other effective
treatment strategies. Developing an animal model for
subjects with moderately reduced GFR and progressive GFR
decline would assist the elucidation of these contributing
mechanisms.
Animals with severely reduced nephron mass have pro-
gressive kidney injury5,6 with GFR decline6–8 that is mediated
by metabolic acidosis and ameliorated by dietary alkali.5,6,8
Similarly, humans with very low GFR and metabolic acidosis
experience progressive kidney injury9 with decline of eGFR9
or creatinine clearance10 that is ameliorated by oral alkali
as NaHCO3
10 or Naþ citrate.9 Endothelins mediate GFR
decline in 5/6 nephrectomy animals with metabolic acidosis,6
and aldosterone mediates glomerulosclerosis in this model.11,12
Nevertheless, progressive GFR decline occurred in the afore-
mentioned subjects with moderately reduced GFR without
metabolic acidosis by plasma acid-base parameters.4 Conse-
quently, whether endothelins and/or aldosterone mediate GFR
decline in subjects with moderately reduced GFR without
metabolic acidosis is not clear.
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Animals with 2/3 compared with 5/6 nephrectomy have
no metabolic acidosis, yet have progressive GFR decline,8 and
so might model human subjects with moderately reduced
GFR without metabolic acidosis who nevertheless have
progressive GFR decline.4 Metabolic acidosis increases kidney
endothelins6 and plasma aldosterone13 and so endothelin-
and/or aldosterone-mediated GFR decline might occur only
when metabolic acidosis accompanies reduced GFR. Conse-
quently, progressive GFR decline in subjects with moderately
reduced GFR and in animals with 2/3 nephrectomy might
occur by mechanisms distinct from endothelins and/or
aldosterone. On the contrary, GFR decline in animals with
2/3 nephrectomy was mediated by underlying acid (Hþ )
retention without metabolic acidosis.8 Whether Hþ reten-
tion without metabolic acidosis by plasma acid-base para-
meters can induce endothelin- and/or aldosterone-mediated
GFR decline in 2/3 nephrectomy is unknown. If so,
determining whether the GFR-preserving effects of dietary
alkali in 2/3 nephrectomy8 were overlapping with or distinct
from any endothelin and/or aldosterone effects has important
mechanistic and possibly therapeutic implications.
The present studies used 2/3 nephrectomy in rats to model
progressive GFR decline in humans with moderately reduced
GFR to explore whether (1) endothelins and/or aldosterone
mediates GFR decline as reported in 5/6 nephrectomy, (2)
endothelin- and/or aldosterone-mediated GFR decline is
induced by Hþ retention without metabolic acidosis, and (3)
the GFR-preserving effects of dietary alkali are mediated
through or distinct from endothelin and/or aldosterone.
RESULTS
Table 1 shows that plasma acid-base parameters and urine net
acid excretion (UNAE) were not different between 2/3 Nx
(hereafter, ‘Nx’) and Sham, but Nx had higher microdialysate
Hþ addition, consistent with greater Hþ retention. Other
Nx received dietary Ca(HCO3)2 (NxþCaHCO3) sufficient to
reduce Hþ retention associated with Nx (ref. 8) compared
with Sham (Materials and Methods). Consequently, Table 1
shows that net Hþ addition to kidney cortical microdialysate
was lower in NxþCaHCO3 than in Nx. Nxþ darusen-
tanþ eplerenone had lower plasma TCO2 than Nx not given
either drug, but acid-base parameters were not different in
Nx given either drug alone. Acid-base parameters in Table 1
were not different among NxþCaHCO3 with or without
darusentan or eplerenone alone or in combination. Table 2
shows no differences in tail cuff blood pressures among
groups.
Figure 1 shows the effects of time following nephrectomy
and endothelin A receptor (ETA) and/or mineralocorticoid
antagonism on GFR measured in conscious animals at weeks 1
and 24 after nephrectomy. Figure 1a shows that week-1 GFR was
lower in Nx than in Sham (2573±189 vs 4198±341ml/min,
Table 1 | Arterial plasma pH/PCO2/TCO2, urine NAE, and net H
+ addition to kidney cortical microdialysate 25 weeks after kidney
mass reduction
Arterial pH
Arterial TCO2
(mmol/l)
Arterial PCO2
(mmol/l)
NAE
(mmol/l/d)
Net H+ addition
(fmol)
Nx 7.41±0.02 24.7±0.5 37.8±1.1 2.9±0.4 515±92
Sham 7.41±0.03 24.9±0.4 38.3±1.0 3.1±0.4 36±48*
Nx 7.40±0.03 24.5±0.5 39.3±1.1 3.0±0.3 448±80
Nx+darusentan 7.39±0.02 24.6±0.5 39.5±1.2 2.7±0.3 529±97
Nx+vehicle 7.40±0.03 24.3±0.6 38.2±1.3 2.9±0.3 433±78
Nx 7.39±0.03 25.0±0.5 40.0±1.2 2.9±0.2 397±68
Nx+eplerenone 7.39±0.03 24.3±0.4 39.2±1.1 2.5±0.2 579±101
Nx+vehicle 7.39±0.04 24.7±0.7 39.7±1.2 2.8±0.2 447±81
Nx+darusentan 7.39±0.03 24.0±0.5 38.4±1.1 2.7±0.3 522±70
Nx+darusentan+eplerenone 7.36±0.03 23.1±0.4 38.0±1.0 2.5±0.2 625±78
Nx+eplerenone 7.38±0.03 23.9±0.5 38.9±1.2 2.5±0.2 503±63
Nx+eplerenone+darusentan 7.38±0.03 23.5±0.4 38.4±1.1 2.4±0.2 486±51
Nx 7.40±0.03 25.2±0.5 39.9±1.1 3.0±0.3 455±72
Nx+darusentan+eplerenone 7.38±0.03 23.5±0.4* 38.4±1.1 2.4±0.2 636±88
Nx 7.40±0.03 24.9±0.5 39.2±1.0 2.9±0.3 505±70
Nx+CaHCO3 7.40±0.02 25.6±0.5 40.3±1.1 1.1±0.2* 25±42*
Nx+CaGlu 7.39±0.03 24.6±0.6 39.7±1.0 3.0±0.3 471±52
Nx+CaHCO3 7.41±0.03 25.1±0.5 38.6±1.1 1.0±0.1 10±34*
Nx+CaHCO3+darusentan 7.40±0.02 25.0±0.5 39.3±1.2 1.1±0.2 19±30
Nx+CaHCO3+vehicle 7.38±0.03 24.9±0.6 41.0±1.2 1.2±0.2 15±21
Nx+CaHCO3 7.40±0.03 25.3±0.5 39.8±1.1 0.9±0.2 33±48
Nx+CaHCO3+eplerenone 7.40±0.03 25.4±0.6 40.1±1.2 1.1±0.2 9±26
Nx+CaHCO3+vehicle 7.39±0.03 25.5±0.6 41.1±1.9 1.0±0.1 35±45
Nx+CaHCO3 7.39±0.03 25.2±0.5 40.6±1.1 1.2±0.2 14±25
Nx+CaHCO3+darusentan+eplerenone 7.38±0.03 25.4±0.6 41.9±1.2 1.0±0.2 27±25
Abbreviations: NAE, net acid excretion; TCO2, total CO2.
N=8 animals in each group.
Values are means±s.e. Nx=2/3 nephrectomy; darusentan is the endothelin A receptor antagonist; eplerenone is the mineralocorticoid receptor antagonist; Ca(HCO3)2 and
calcium gluconate (CaGlu) were added to diets of the indicated groups. All animals ingested diets containing casein as protein. *Po0.05 vs respective index value.
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Po0.001) as expected and that week-24 GFR was not
different from its respective week-1 value in Sham
(4109±322 ml/min, P¼ 0.71 vs week-1 value). By contrast,
week-24 GFR for Nx (1785±125 ml/min) was lower than at
week 1 (Po0.001, paired t-test, vs week 1 value) and was
lower than week-24 Sham GFR (Po0.001). Figure 1b shows
that week-1 GFR was not different among Nx given the ETA
receptor antagonist darusentan, vehicle, and Nx given no
additional treatment, and that week-24 GFR was lower than
the respective week-1 value in all three groups. Week-24 GFR
was higher in Nxþ darusentan (2402±169 ml/min) than in
Nx and Nxþ vehicle (1744±119 and 1731±124 ml/min,
respectively, P¼ 0.02, analysis of variance (ANOVA), vs
Nxþ darusentan). Similar to the darusentan data, Figure 1c
shows that week-1 GFR was not different among Nx given the
mineralocorticoid receptor antagonist eplerenone, vehicle,
and Nx given no additional treatment, and that week-24 GFR
was lower than the respective week-1 value in all three
groups. Week-24 GFR was higher in Nxþ eplerenone
(2281±150 ml/min) than in Nx and Nxþ vehicle
(1711±117 and 1755±120 ml/min, respectively, P¼ 0.013,
ANOVA, vs Nxþ eplerenone). Not shown in Figure 1,
week-24 compared with week-1 GFR was also lower in
Nxþ darusentanþ eplerenone (2508±162 vs 2618±169 ml/
min, P¼ 0.04, paired t-test) but GFR at week 24 was higher
in Nxþ darusentanþ eplerenone than in Nx (2508±162 vs
1750±132 ml/min, Po0.001).
Figure 2 shows the effects of time following nephrectomy
and of dietary alkali as CaHCO3 on GFR in conscious
animals at weeks 1 and 24 after nephrectomy. Figure 2a
shows that week-1 GFR was not different (P¼ 0.823) among
Nx (2714±178 ml/min), NxþCaHCO3 (2658±179 ml/min),
and NxþCa2þ gluconate (CaGlu) (2679±172 ml/min).
Figure 2a also shows that, although week-24 GFR was lower
Table 2 | Tail cuff systolic blood pressure in conscious animals
in mmHg (n=8 animals for all groups)
Sham Nx P-value
100±2 113±4a 0.012
Nx Nx+darusentan Nx+vehicle
112±5 108±4 111±4 0.794
Nx Nx+eplerenone Nx+vehicle
111±4 110±5 113±4 0.889
Nx Nx+darusentan+eplerenone —
114±4 104±3a 112±4 0.196
Nx Nx+CaHCO3 Nx+CaGlu
110±3 112±4 112±3 0.815
Nx+CaHCO3 Nx+darusentan+eplerenone —
111±3 105±3 — 0.538
aDifference from respective value in column 1.
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Figure 1 |Bar graphs comparing effects of 2/3 surgical nephron mass reduction of the endothelin A receptor antagonist darusentan
or vehicle, and of the mineralocorticoid receptor antagonist eplerenone or vehicle, on glomerular filtration rate (GFR, ll/min) in
conscious Sham and nephrectomized (Nx) animals at weeks 1 and 24 after Nx. (a) Comparison of Sham and Nx. (b) Comparison of Nx
given darusentan, vehicle, or neither. (c) Comparison of Nx given eplerenone, vehicle, or neither. *Po0.05 vs index value; þPo0.05 vs
1-week value within groups.
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Figure 2 |Bar graphs comparing effects of dietary alkali as
CaHCO3 and of CaHCO3 given darusentanþ eplerenone on
glomerular filtration rate (GFR) (ll/min) in conscious
nephrectomized (Nx) animals at weeks 1 and 24 after Nx.
(a) Comparison of NxþCaHCO3 with Nx and Nxþ calcium
gluconate (CaGlu) to control for dietary calcium without providing
alkali. (b) Comparison of NxþCaHCO3 with Nx given darusentanþ
eplerenone. *Po0.05 vs index value; þPo0.05 is 1-week value
within groups.
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than the respective week-1 values for Nx and NxþCaGlu,
week-24 GFR NxþCa HCO3 was not different from its
respective week-1 value (2584±165 ml/min, P¼ 0.091) and
this GFR was higher than the week-24 GFRs for Nx and
NxþCaGlu (Po0.001, ANOVA). Figure 2b shows that
adding darusentan and eplerenone had no significant
influence on GFR in animals already receiving CaHCO3.
Specifically, GFR was not different between NxþCaH-
CO3þ darusentanþ eplerenone and NxþCaHCO3 at week
1 (2629±165 and 2642±171 ml/min, respectively, P¼ 0.957)
or at week 24 (2616±158 and 2577±160 ml/min, respec-
tively, P¼ 0.865) and the week-24 compared with week-1
GFRs were not different for NxþCaHCO3þ
darusentanþ eplerenone (P¼ 0.178) or for NxþCaHCO3
(P¼ 0.362). These data support that darusentan and
eplerenone were not additive to CaHCO3 in preserving GFR.
Figure 3 compares ET-1 and aldosterone addition to
kidney cortical microdialysate among groups at week 25
following nephrectomy. Figure 3a shows higher microdialy-
sate ET-1 addition in Nx than in Sham (1063±113 vs
254±31 fmol/min, Po0.001). Figure 3b shows that ET-1
addition for NxþCaHCO3 (386±42 fmol/min) was lower
(Po0.001, ANOVA) than for both Nx (1113±121 fmol/min)
and NxþCaGlu (1004±118 fmol/min). Similarly, Figure 3c
shows higher microdialysate aldosterone addition in Nx than
in Sham (352±50 vs 92±11 fmol/min, Po0.001). Figure 3d
shows that aldosterone addition for NxþCaHCO3
(159±17 fmol/min) was lower (P¼ 0.003, ANOVA) than
that for both Nx (423±62 fmol/min) and NxþCaGlu
(367±40 fmol/min). These data support than CaHCO3
lowered both ET-1 and aldosterone addition to kidney
microdialysate. Not shown in Figure 3, aldosterone addition
for Nxþ darusentan (200±22 fmol/min) was lower
(P¼ 0.030, ANOVA) than that for Nx without darusentan
(379±56 fmol/min) and Nxþ vehicle (349±47 fmol/min).
By contrast, ET-1 addition for Nxþ eplerenone (881±92
fmol/min) was not different (P¼ 0.603, ANOVA) between
Nx (957±109 fmol/min) and Nxþ vehicle (1060±113 fmol/
min). These data suggest than ETA receptor antagonism
reduced aldosterone addition to microdialysate but that
mineralocorticoid receptor antagonism did not reduce ET-1
addition. Also not shown in Figure 3, ET-1 addition to
microdialysate in NxþCaHCO3þ darusentanþ eplerenone
animals was not different from that in NxþCaHCO3
(405±41 vs 344±35 fmol/min, P¼ 0.277). Similarly, aldos-
terone addition in NxþCaHCO3þ darusentanþ eplerenone
animals was not different from that of NxþCaHCO3
(181±19 vs 149±18 fmol/min, P¼ 0.242). These data
support that darusentan and eplerenone were not additive
to CaHCO3 in lowering ET-1 and aldosterone addition to Nx
microdialysate.
Figure 4 compares plasma ET-1 and aldosterone concen-
trations among groups at week 25 following nephrectomy.
Figure 4a shows higher plasma ET-1 in Nx than in Sham
(6.02±0.47 vs 4.10±0.31 fmol/ml, P¼ 0.004). Figure 4b
shows that plasma ET-1 for NxþCaHCO3 (4.26±0.33
fmol/ml) was lower (P¼ 0.020, ANOVA) than that for both
Nx (5.91±0.40 fmol/ml) and NxþCaGlu (6.21±0.48
fmol/m1). Similarly, Figure 4c shows higher plasma aldoster-
one in Nx than in Sham (947±111 vs 492±54
fmol/ml, P¼ 0.002). Figure 4d shows that plasma aldosterone
for NxþCaHCO3 (553±62 fmol/ml) was lower (P¼ 0.032,
ANOVA) than that for both Nx (905±102 fmol/min) and
NxþCaGlu (875±104 fmol/min).
Because ETA and mineralocorticoid antagonists are
associated with fluid retention14 and hyperkalemia,15
respectively, we compared body weights and serum Kþ in
Nx that were administered and not administered these drugs
24 weeks after kidney mass reduction. Body weight was
higher in Nxþ darusentan (n¼ 16) than in Nx (n¼ 32)
(278±5.2 vs 256±5.1 g, P¼ 0.01) but was not higher in
Nxþ eplerenone (n¼ 16) (262±5.0 g, P¼ 0.46 vs Nx).
Serum Kþ was higher in Nxþ eplerenone than in Nx
(6.0±0.3 vs 4.7±0.2meq/l, Po0.001) but was not higher
in Nxþ darusentan (n¼ 16) (5.0±0.2meq/l, P¼ 0.35
vs Nx).
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Figure 3 |Bar graphs comparing endothelin-1 (ET-1) and
aldosterone (Aldo) addition to kidney cortical microdialysate
in conscious animals at week 25 after 2/3 Nx. (a) Comparison
of ET-1 addition in Sham and Nx. (b) Comparison of ET-1 addition
among Nx given dietary alkali as CaHCO3 or non-alkalizing CaGlu
with Nx given neither. (c) Comparison of Aldo addition in Sham
and Nx. (d) Comparison of Aldo addition among Nx given CaHCO3
or CaGlu with those given neither salt (Nx). *Po0.05 vs index
value.
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DISCUSSION
Metabolic acidosis induces progressive GFR decline in 5/6
nephrectomy through endothelin receptors,6 and aldosterone
mediates GFR decline11 and glomerulosclerosis12 in this same
model. Two-thirds nephrectomy animals consuming Hþ -
inducing diets have progressive GFR decline as well, despite
not having metabolic acidosis as reflected by plasma acid-
base parameters.8 Although these 2/3 nephrectomy animals
do not have metabolic acidosis, they have Hþ retention that
induces GFR decline, and its reduction with dietary alkali
preserves GFR.8 Because endothelin6 and aldosterone11,12
mediate GFR decline and kidney injury in 5/6 nephrectomy
with metabolic acidosis, we explored whether endothelin
and/or aldosterone mediates GFR decline induced by Hþ
retention in 2/3 nephrectomy animals without metabolic
acidosis. These 2/3 nephrectomy animals might model
subjects with moderately reduced GFR who have progressive
GFR decline3,4 and thereby yield insights into mechanisms by
which GFR declines in subjects with moderately reduced GFR
and why daily oral NaHCO3 slows GFR decline and
ameliorates kidney injury in these subjects.4 The data show
that Hþ retention associated with 2/3 nephrectomy increases
kidney and plasma ET-1 and aldosterone levels and that GFR
decline in this model is mediated through endothelin and
aldosterone receptors. Although endothelin receptor antag-
onism lowered kidney aldosterone levels in 2/3 nephrectomy,
consistent with endothelin-stimulated aldosterone secre-
tion,16 GFR preservation was similar with endothelin and
aldosterone receptor antagonism given each alone or in
combination. Furthermore, reduction of Hþ retention in 2/3
nephrectomy to Sham levels with dietary alkali lowered
kidney ET-1 and aldosterone levels and better preserved GFR
than endothelin and aldosterone receptor antagonism alone
or combined. The data support that endothelin and
aldosterone mediate GFR decline induced by Hþ retention
in 2/3 nephrectomy animals without metabolic acidosis and
that dietary alkali that normalizes Hþ retention preserves
GFR better than combined ETA and mineralocorticoid
receptor antagonism.
Although dietary alkali as Ca(HCO3)2 and endothelin
and/or aldosterone antagonism each led to better GFR
preservation, dietary alkali but not receptor antagonism was
associated with no statistically significant GFR decline. There
were also no significant differences in blood pressure among
groups that might have improved GFR preservation. Table 1
shows that the receptor antagonists had no effect on Hþ
retention. The data support that mechanisms in addition to
endothelin and aldosterone contribute to GFR decline
induced by Hþ retention in 2/3 nephrectomy. Other
mechanisms possibly induced by Hþ retention that might
mediate GFR decline in Nx animals include angiotensin II,17
oxidative stress,18 and complement activation,5,19 none of
which was examined presently. Whatever additional mechan-
isms mediate GFR decline induced by Hþ retention in 2/3
nephrectomy, the data support that dietary alkali better
preserves GFR in this model than either receptor antagonist
alone or in combination.
Subjects with CKD and reduced GFR due to hypertensive
nephropathy might have progressive GFR decline despite
improved blood pressure control and ACE inhibition.3,4
Because diets in industrialized societies are largely Hþ
inducing 20 and dietary Hþ induces urine NAE excretion in
humans that is less than the dietary-Hþ -induced increase in
intrinsic Hþ production,21 Hþ retention with or without
metabolic acidosis might contribute to progressive GFR
decline in human nephropathy with reduced GFR. Dietary
alkali as Naþ citrate better preserved GFR in those subjects
with metabolic acidosis associated with severely reduced GFR
(mean eGFR¼ 33ml/min) due to hypertensive nephropathy
who also received ACE inhibition.9 In human studies
analogous to the animal studies described herein, 5 years of
daily oral NaHCO3 better preserved GFR in those subjects
with moderately reduced GFR (mean eGFR¼ 75ml/min)
due to hypertensive nephropathy but without metabolic
acidosis who also received ACE inhibition.4 Subjects with
chronically reduced GFR, such as animals with chronic
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Figure 4 |Bar graphs showing plasma endothelin-1 (ET-1) and
aldosterone (Aldo) concentrations in conscious animals at
week 25 after 2/3 Nx. (a) Comparison of plasma ET-1 in Sham
and Nx and (b) comparison of ET-1 addition among Nx given
dietary alkali as CaHCO3 or the non-alkalizing CaGlu with Nx given
neither. (c) Comparison of plasma Aldo concentration in Sham
and Nx. (d) Comparison of Aldo addition among Nx given CaHCO3
or CaGlu with those given neither salt (Nx). *Po0.05 vs index value.
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nephrectomy, must mount the same Hþ excretion as those
with intact nephron mass in order to maintain Hþ balance
when each consumes diets of the same acid/base content.22,23
Humans with reduced GFR can achieve Hþ excretion
equivalent to intrinsic Hþ production23 and maintain
normal plasma acid-base parameters,24 but might do so in
a setting of Hþ retention, such as the 2/3 nephrectomy
animals of previous 8 and present studies. Earlier studies of
2/3 Nx animals showed Hþ retention in skeletal muscle in
addition to kidney cortex,8 supporting the fact that Hþ
retention associated with reduced GFR is a systemic
phenomenon and is not limited to the kidney. Such Hþ
retention in humans with reduced GFR might increase
kidney and possibly systemic production of endothelin-1 as
suggested in remnant kidney animals with metabolic
acidosis6 and of aldosterone in humans given dietary acid.13
In vitro studies show that an acid extracellular environment
increases endothelin-1 release from human glomerular
endothelial cells25 and that more acid perfusate increases
aldosterone release from isolated perfused adrenal glands.26 If
subsequent investigations do indeed show that humans with
reduced GFR have Hþ retention, follow-up studies will
determine whether this Hþ retention induces GFR decline in
human nephropathy, as in animal models, and will determine
whether endothelins and/or aldosterone are its mediators.
Other investigators have explored whether endothelin14 and
aldosterone15 receptor antagonists ameliorate markers of
kidney injury, trying to determine whether they might be
effective kidney-protective agents. Nevertheless, both classes
of agents induce potentially life-threatening complications in
a high proportion of subjects, including fluid retention and
heart failure with endothelin antagonists14 and hyperkalemia
with aldosterone antagonists.15 Greater body weights in
animals given darusentan and the higher serum Kþ in those
given eplerenone in the present studies support these
concerns. These agents also substantially increase the cost
of CKD management. On the other hand, if humans with
reduced GFR indeed have Hþ retention, the present studies
suggest testing the comparatively inexpensive and well-
tolerated therapy of dietary alkali as kidney-protective
therapy that, by reducing Hþ retention, might remove a
stimulus of increased endothelin and aldosterone secretion
and thereby avoid use of endothelin and/or aldosterone
receptor antagonists. The evidence that dietary alkali
preserves GFR in hypertensive and other nephropathies4,9,10
supports this research direction.
The present studies along with others from our laboratory
and laboratories of others support a contributing role for Hþ
retention in progressive GFR decline in subjects with
moderately reduced GFR. We propose that systemic Hþ
retention ensues when GFR falls in animals or subjects
ingesting an Hþ -inducing diet such that overall kidney Hþ
excretion temporarily falls below intake. In this setting, Hþ
retention increases until the kidney completes the necessary
adjustments to increase per-nephron Hþ excretion in the
remaining functioning nephrons to restore overall kidney
Hþ excretion to match continued Hþ intake. Consequently,
a new steady state is established in which net Hþ balance
(Hþ in¼Hþ out) is restored but with the consequence of
sustained Hþ retention. In support of this proposal, systemic
Hþ retention induced by increased dietary Hþ intake is
chronically maintained with normal plasma acid-base para-
meters in animals with intact nephron mass as long as
increased dietary Hþ intake continues and resolves only after
the increment in dietary Hþ is discontinued.27 We further
propose that Hþ retention increases kidney endothelin and
aldosterone activity that contributes to the physiologically
beneficial increase in distal nephron acidification in response
to the increment in dietary Hþ .28 We propose that Hþ
retention occurs in animals and subjects with reduced GFR as
described, and is maintained as long as they ingest the Hþ -
inducing diets typical of laboratory animal chow and in
humans consuming the Hþ -inducing diets typical of
industrialized societies.20 We propose that the Hþ reten-
tion-induced increase in kidney endothelin and aldosterone
production also contributes to pathophysiological GFR
decline as described. Because the data show that dietary
alkali better preserves GFR than combined endothelin and
aldosterone antagonism, Hþ retention appears to induce
GFR decline through mechanisms in addition to endothelin
and aldosterone. These data support that dietary alkali
removes a stimulus for increased endothelin and aldosterone
production and suggest that this simple dietary maneuver
also ameliorates other mechanisms that contribute to GFR
decline in this setting.
In summary, the present studies used 2/3 nephrectomy in
rats to model subjects with moderately reduced GFR and
progressive GFR decline to show that Hþ retention in 2/3
nephrectomy animals increased kidney ET-1 and aldosterone
levels that mediated GFR decline in this model of CKD
without metabolic acidosis. Dietary alkali as Ca(HCO3)2
better preserved GFR than did endothelin or aldosterone
receptor antagonism alone or in combination, and receptor
antagonism was not additive to dietary alkali in preserving
GFR. Further studies will help to determine whether humans
with moderately reduced GFR and progressive GFR decline
have Hþ retention that induces endothelin- and aldosterone-
mediated GFR decline. While awaiting completion of such
studies, it seems prudent to continue testing dietary alkali as
an adjunctive kidney-protective intervention to blood
pressure reduction and ACE inhibition in subjects with both
severe9,10 and moderate4 GFR reduction. This kidney-
protective intervention is a less expensive, possibly more
effective, and better-tolerated alternative to endothelin and/
or aldosterone receptor antagonism.
MATERIALS AND METHODS
Animals, diet, and protocol
Male and female Munich-Wistar rats (8 weeks old; Harlan Sprague-
Dawley, Houston, TX) were fed standard rat chow (Prolab RMH
2500 with 23% protein of various sources; Purina Labs, St Louis,
MO) before kidney mass reduction surgery. Because daily NaHCO3
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slows GFR decline in subjects with moderately reduced eGFR and
plasma acid-base parameters not different from subjects with
normal eGFR,4 we sought an animal model of such subjects.
Endothelins6 and aldosterone11,12 mediated kidney injury and
GFR decline in 5/6 nephrectomy with metabolic acidosis, and
dietary alkali ameliorated kidney injury and GFR decline in this
model.5,6 Unlike conscious 5/6 nephrectomy animals that had lower
arterial plasma total CO2 (PTCO2) than did Sham
6 by ultrafluoro-
metry,29 plasma PTCO2 by ultrafluorometry was comparable in
conscious 2/3 Nx and Sham animals despite greater kidney and
skeletal muscle Hþ content in 2/3 Nx.8 Consequently, we used 2/3
Nx to determine whether endothelins and/or aldosterone mediated
GFR decline and whether dietary alkali lowered kidney ET-1 and
aldosterone measured in vivo using microdialysis.8,27 After kidney
mass reduction, animals were fed minimum electrolyte diets with
20% protein as casein (ICN Nutritional Biochemicals, Cleveland,
OH) and had access to distilled H2O. We compared GFR at 1 and 24
weeks after nephron mass reduction (the latter time point labeled 25
weeks), rather than at 12 weeks,8 to allow for greater GFR decline.
To examine endothelin and aldosterone as potential mediators of
GFR decline in animals with reduced GFR and Hþ retention
without metabolic acidosis, other animals received dietary Ca2
(HCO3)2 to reduced H
þ retention without increasing blood
pressure.6 Doing so compared Nx with Hþ retention but without
metabolic acidosis to Nx without either metabolic acidosis or Hþ
retention measured in vivo using microdialysis of kidney cortex.8,27
We found that, similar to Sham, Nx fed diets with 125 mmol/g diet
per day of added Ca2(HCO3)2 had no net H
þ addition to
microdialysate (see below). Nx fed 125mmol/g diet per day of
Ca2þ gluconate were compared with control for dietary Ca2þ .8 Nx
and similar weight controls were fed 17.8±0.9 vs 20.4±0.8 g/day,
respectively (n¼ 4, P¼ 0.07), and hence all received a diet of 17 g/
day. Some received the ETA antagonist darusentan (Knoll,
Ludwigshafen/Rhein, Germany)30 mixed with diet at 20mg/kg body
wt per day. This oral dose reduced glomerulosclerosis and
proteinuria in a puromycin model of kidney injury.31 Others
received eplerenone (Pfizer, New York, NY) mixed with diet at
100mg/kg body wt per day, an oral dose that reversed kidney
fibrosis in the deoxycorticosterone/salt rat.32 Tail cuff blood pressure
was measured as described previously.6
Kidney mass reduction
Nx was induced by surgical removal of approximately 2/3 of kidney
mass in two stages and chronic vascular lines were inserted.8 One
week after the second surgery, during which animals were fed the
described experimental diet, GFR was measured in conscious Nx
and Sham by slope of the decrease in plasma concentration of
intravenously infused 3H-inulin over 180min.33
Microdialysis to compare kidney cortical Hþ , ET-1, and
aldosterone
At 23 weeks after the second surgery, during which animals were fed
the experimental diet, Nx and Sham had surgery to insert a
constructed microdialysis catheter into the kidney cortex through a
flank incision.8,27 Relative Hþ retention among Sham, Nx, and
alkali-ingesting Nx was determined by comparing differences in Hþ
content ([Hþ ] times dialysate volume) between collected and
infused dialysate.8,27 Kidney cortical ET-1 and aldosterone content
were compared to determine relative kidney parenchyma exposure
to these substances among the various experimental conditions.
Microdialysis of kidney cortex was carried out in comfortably
restrained, conscious animals 7 days after microdialysis catheter
insertion (24 weeks after kidney mass reduction).8,27 As described
previously,8,27 we designed a dialysate that would gain Hþ when
dialyzed against kidney cortex with higher-than-Sham Hþ content
and would lose Hþ if kidney cortex Hþ were less. This was achieved
using Ringer’s HCO3 with [HCO3]¼ 26meq/l. Three 20-min
collections were carried out in eight animals in each group.
Anaerobically obtained, collected, and infused dialysate was
analyzed for pH (Micro Flow Through pH Monitor; Lazar Research
Labs, Los Angeles, CA), PCO2 (Micro Flow Through CO2 Probe;
Lazar Research Labs), and total CO2 (TCO2) by flow-through
ultrafluorometry.29
Whole blood and plasma parameters
Immediately after microdialysis (24 weeks after kidney mass
reduction), 0.35ml of carotid arterial blood was slowly removed
for arterial blood gases, plasma PTCO2 (by flow-through ultra-
fluorometry), electrolytes, ET-1, and aldosterone from awake, calm,
and gently restrained animals. It was replaced with an equivalent
blood volume from a paired, identically treated animal. The animal
was then returned to its metabolic cage for an additional 1 week.
GFR was repeated, now 24 weeks after initial GFR measurement and
25 weeks after kidney mass reduction.
Urine NAE
Six days after insertion of the microdialysis catheter, urine NAE was
measured34 in a 24-h sample in eight animals each of control and
experimental groups kept in metabolic cages.
Analytical methods
Collected and infused dialysate, arterial plasma, and microdialysate
were immediately analyzed for TCO2 using flow-through ultra-
fluorometry.29 Dialysate and plasma ET-1 were measured as
described previously35 with an RIA kit (Peninsula Laboratories,
Belmont, CA) after extraction using Bound Elut C18 columns
(Varian, Harbor City, CA). Dialysate and plasma aldosterone were
measured after extraction with Bound Elut C18 columns (Varian)
using a radioimmunoassay kit (Diagnostic Products Corporation,
Los Angeles, CA).
Calculations
Urine NAE was the mean for each animal group. Net dialysate Hþ
addition was calculated as described previously.8,27 Positive values
for net Hþ addition indicated greater Hþ content in collected
compared with infused dialysate (that is, Hþ gain) and negative
ones indicated lower Hþ content (that is, Hþ loss). Net Hþ
addition for each of three collection periods was averaged for a
single animal value and averaged for each animal for a group value.
Statistical analysis
Data were expressed as means±s.e. ANOVA (Po0.05) was used for
multiple group comparisons.
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